Connection

Fengcai Zhu to Seroconversion

Back to Details
This is a "connection" page, showing publications Fengcai Zhu has written about Seroconversion.
Fengcai Zhu
Connection Strength
0.503
Seroconversion
  1. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort. J Viral Hepat. 2018 12; 25(12):1588-1598.
    View in: PubMed
    Score: 0.357
  2. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192.
    View in: PubMed
    Score: 0.104
  3. Seroepidemiology of coxsackievirus B5 in infants and children in Jiangsu province, China. Hum Vaccin Immunother. 2018 01 02; 14(1):74-80.
    View in: PubMed
    Score: 0.021
  4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Rev Vaccines. 2017 11; 16(11):1155-1169.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.